Browse Menu >>

Browse Subjects >>

Biomedical & Life Sciences

Business & Economics

Chemistry & Materials Science

Computer Science & Communications

Earth & Environmental Sciences

Engineering

Medicine & Healthcare

Physics & Mathematics

Social Sciences & Humanities

Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.

 

Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
   
Paper Publishing WeChat
Book Publishing WeChat
(or Email:book@scirp.org)

Article citations

More>>

C. M. Grieshop, E. A. Flickinger and G. C. Fahey, Jr., “Oral Administration of Arabinogalactan Affects Immune Status and Fecal Microbial Populations in Dogs,” Journal of Nutrition, Vol. 132, No. 3, 2002, pp. 478-482.

has been cited by the following article:

  • TITLE: Tolerability of a Proprietary Larch Arabinogalactan Extract: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Healthy Subjects

    AUTHORS: Barbara Grube, Heike Stier, Linda Riede, Joerg Gruenwald

    KEYWORDS: Randomized Placebo-Controlled Study; Proprietary Larch Arabinogalactan; Safety; Tolerability; Resist AidTM

    JOURNAL NAME: Food and Nutrition Sciences, Vol.3 No.11, November 20, 2012

    ABSTRACT: In a placebo-controlled, double-blind, randomized clinical trial, the tolerability of a proprietary larch arabinogalactan preparation (ResistAidTM) was investigated. METHODS: 199 healthy participants were randomly assigned to receive either placebo (n = 98) or an arabinogalactan preparation (n = 101) over a period of 12 weeks. As safety parameters the total number of adverse events, changes in various biochemical and laboratory parameters as well as the global evaluation of tolerability by investigator and subjects compared to placebo were evaluated. RESULTS: In total 16 adverse events were observed in 16 subjects, with no difference between the arabinogalactan and the placebo group (p = 0.935). There were no differences in the mean changes of the measured biochemical and laboratory parameters. The tolerability of the arabinogalactan extract was rated as “very good” or “good” by the investigators for 99% of the subjects and by 98% subjects in self-assessment with no statistical differences to placebo. CONCLUSION: The measured parameters as well as the evaluation of the tolerability by the investigators and the subjects demonstrate a very good tolerance profile of the proprietary arabinogalactan extract with no differences to placebo when taken for 12 weeks.